Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications.
about
Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72Evaluation and comparison of human absorbed dose of (90)Y-DOTA-Cetuximab in various age groups based on distribution data in rats.Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.Targeted α-Particle Radiation Therapy of HER1-Positive Disseminated Intraperitoneal Disease: An Investigation of the Human Anti-EGFR Monoclonal Antibody, Panitumumab.PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinomaPotential target antigens for a universal vaccine in epithelial ovarian cancer.Multichannel imaging to quantify four classes of pharmacokinetic distribution in tumorsQuantitating antibody uptake in vivo: conditional dependence on antigen expression levels.Multiplexed Five-Color Molecular Imaging of Cancer Cells and Tumor Tissues with Carbon Nanotube Raman Tags in the Near-Infrared.Cancer radioimmunotherapy.In Vitro and In Vivo Pre-Clinical Analysis of a F(ab')(2) Fragment of Panitumumab for Molecular Imaging and Therapy of HER1 Positive CancersA single chimpanzee-human neutralizing monoclonal antibody provides post-exposure protection against type 1 and type 2 polioviruses.Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease.A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies.Intraoperative imaging in ovarian cancer: fact or fiction?A practical guide to the construction of radiometallated bioconjugates for positron emission tomography.Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody.Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab.Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent.Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and TherapyRadioimmunotherapy of solid tumors: searching for the right target.Selecting Potential Targetable Biomarkers for Imaging Purposes in Colorectal Cancer Using TArget Selection Criteria (TASC): A Novel Target Identification Tool.Comparative studies on the therapeutic benefit of targeted α-particle radiation therapy for the treatment of disseminated intraperitoneal disease.Structure-based drug design and biological evaluation of 2-acetamidobenzothiazole derivative as EGFR kinase inhibitor.Cytotoxic properties of radionuclide-conjugated Cetuximab without and in combination with external irradiation in head and neck cancer cells in vitro.Flow cytometric cell-based assay to preselect antibody constructs for radionuclide conjugation.Cellular and molecular properties of (90)Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro.Nanomedicine for the treatment of triple-negative breast cancer.Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus.Novel PAMAM-PEG-Peptide Conjugates for siRNA Delivery Targeted to the Transferrin and Epidermal Growth Factor Receptors.Sensitization of Radiation or Gemcitabine-Based Chemoradiation Therapeutic Effect by Nimotuzumab in Pancreatic Cancer Cells.Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model.Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography.
P2860
Q28272255-BA5D94E8-591A-49D0-9B9F-CDF587800514Q30584781-CFBCDF1B-C432-4BBB-A3EF-70BF172104A7Q33661325-89E32E75-9076-4F9E-8272-C1616AB187ABQ33761180-43BB1A44-AD05-4777-8C4C-EBFFE52E0FBCQ33939881-B897413A-61A3-4874-86B5-3649ADAE3851Q33943630-1EBD3062-64A0-4642-B23D-3EBE209C6821Q34159451-29693BA3-C082-4A81-AA76-EF92079A4B02Q34241923-6D6F15A3-0A30-4565-991A-A133803D18B1Q34400470-81274DF7-1C58-4373-8042-5EB78BCA16AEQ34710809-95CEFC4D-D7CD-4C9D-938B-1C9D91C88494Q35070045-278DA9C9-4D7E-4E05-8EFA-66ED0E441969Q35162293-35AD9F3A-358B-4804-9A7E-AD00C345D94BQ35228866-0D8253B8-8370-429C-84FC-57ACA45FBB37Q36213374-13441346-48EE-444A-97BF-EDB5B448C6A1Q36459800-AF803914-F3A0-4569-AF1F-48B913FBC230Q37149571-E700EE9E-4409-4274-91E8-62AEA7EC5F95Q37172093-15202161-B39B-41CD-BED6-01671798DC23Q37244880-1D3B247D-132D-4AAB-B165-CF77E0082910Q37317530-B0DBFE89-C899-40A8-B583-FD253A19C9E9Q37395272-254AD817-D008-45F6-A1BF-921EA109BC2BQ37689802-154814E5-FCA2-4990-8F39-729211831B2AQ37804904-3C070508-9761-4CE4-A89F-6133A184C5C4Q37860943-0F40FBA2-9D6F-4647-ACAC-D6B1ABC3395DQ38663041-10486C7F-FDC3-486C-A0AD-99218583E0EAQ39018134-3CB13BA7-551C-4954-8C29-9A773BDEA4D3Q39018435-A9FB7618-F677-4CB0-BCCB-F1CC0FC6658EQ39289085-2A98EC16-18ED-4AF7-B856-0DF6D653DB85Q39300555-D11E5F16-A908-4844-9D4A-C686F0C3D640Q45758946-D4C46932-601D-4192-9333-EFC49741EFBCQ47134709-BBD77A37-D158-47C6-A35C-5B2A0223BEE5Q48284313-F7442B9A-B354-4B4E-8875-F16F61F4B0C3Q52942376-A135CD15-BDB2-4389-8A9A-800ABD1A6B7EQ53265601-25C3BADF-67C4-4FBC-BE41-1F3499032B0FQ54336425-A181CCDA-00A3-4CC7-9678-33C2CE2EA601
P2860
Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Cetuximab: preclinical evaluat ...... mmunotherapeutic applications.
@en
type
label
Cetuximab: preclinical evaluat ...... mmunotherapeutic applications.
@en
prefLabel
Cetuximab: preclinical evaluat ...... mmunotherapeutic applications.
@en
P2093
P2860
P356
P1476
Cetuximab: preclinical evaluat ...... mmunotherapeutic applications.
@en
P2093
Diane E Milenic
Geoffrey L Ray
Karen J Wong
Kayhan Garmestani
Kwamena E Baidoo
Mark Williams
Martin W Brechbiel
P2860
P304
P356
10.1089/CBR.2008.0493
P577
2008-10-01T00:00:00Z